Phase II evaluation of menogaril in patients with advanced hypernephroma
| Autor: | Harry J. Long, Stephen Frytak, Mark D. Hauge, Jan C. Buckner, Richard G. Hahn, Terry M. Therneau |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Urology Antineoplastic Agents Neutropenia medicine.disease_cause Infusion Site Drug Administration Schedule chemistry.chemical_compound Leukocyte Count Renal cell carcinoma medicine Humans Pharmacology (medical) Platelet Carcinoma Renal Cell Aged Pharmacology Chemotherapy business.industry Platelet Count Nogalamycin Menogaril Middle Aged medicine.disease Kidney Neoplasms Surgery Oncology chemistry Toxicity Drug Evaluation Female Irritation business |
| Zdroj: | Investigational new drugs. 9(3) |
| ISSN: | 0167-6997 |
| Popis: | Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink